Hoth Therapeutics (NASDAQ:HOTH) Given Speculative Buy Rating at Benchmark

Benchmark reissued their speculative buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a report issued on Friday, Benzinga reports. They currently have a $3.00 price objective on the stock.

A number of other analysts also recently weighed in on HOTH. HC Wainwright reaffirmed a buy rating and issued a $4.00 target price on shares of Hoth Therapeutics in a research report on Friday, August 16th. EF Hutton Acquisition Co. I raised shares of Hoth Therapeutics to a strong-buy rating in a research note on Wednesday, August 21st.

Hoth Therapeutics Trading Up 1.2 %

Shares of NASDAQ HOTH opened at $0.75 on Friday. The firm has a fifty day simple moving average of $0.82 and a two-hundred day simple moving average of $0.99. The firm has a market capitalization of $5.18 million, a PE ratio of -0.47 and a beta of 0.84. Hoth Therapeutics has a 12 month low of $0.58 and a 12 month high of $1.73.

Hoth Therapeutics (NASDAQ:HOTH) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.15. On average, sell-side analysts predict that Hoth Therapeutics will post -1.18 earnings per share for the current year.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.